ID   ABL1_HUMAN              Reviewed;        1130 AA.
AC   P00519; A3KFJ3; Q13869; Q13870; Q16133; Q17R61; Q45F09;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 4.
DT   12-OCT-2022, entry version 276.
DE   RecName: Full=Tyrosine-protein kinase ABL1;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:28428613};
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 1;
DE   AltName: Full=Abelson tyrosine-protein kinase 1;
DE   AltName: Full=Proto-oncogene c-Abl;
DE   AltName: Full=p150;
GN   Name=ABL1; Synonyms=ABL, JTK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA), ALTERNATIVE SPLICING, CHROMOSOMAL
RP   TRANSLOCATION WITH BRC, AND VARIANT PRO-140.
RX   PubMed=3021337; DOI=10.1016/0092-8674(86)90450-2;
RA   Shtivelman E., Lifshitz B., Gale R.P., Roe B.A., Canaani E.;
RT   "Alternative splicing of RNAs transcribed from the human abl gene and from
RT   the bcr-abl fused gene.";
RL   Cell 47:277-284(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA).
RC   TISSUE=Fibroblast;
RX   PubMed=2687768;
RA   Fainstein E., Einat M., Gokkel E., Marcelle C., Croce C.M., Gale R.P.,
RA   Canaani E.;
RT   "Nucleotide sequence analysis of human abl and bcr-abl cDNAs.";
RL   Oncogene 4:1477-1481(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS IA AND IB).
RC   TISSUE=Lung;
RX   PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and regions
RT   involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-706; PRO-852; SER-900
RP   AND LEU-972.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IB).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-40, AND SUBCELLULAR COMPONENT.
RX   PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P., Dreazen O.,
RA   Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 360-426.
RX   PubMed=6191223; DOI=10.1038/304167a0;
RA   Groffen J., Heisterkamp N., Reynolds F.H. Jr., Stephenson J.R.;
RT   "Homology between phosphotyrosine acceptor site of human c-abl and viral
RT   oncogene products.";
RL   Nature 304:167-169(1983).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 825-845.
RX   PubMed=7545908;
RA   Inokuchi K., Futaki M., Dan K., Nomura T.;
RT   "Sequence analysis of the mutation at codon 834 and the sequence variation
RT   of codon 837 of c-abl gene.";
RL   Leukemia 8:343-344(1994).
RN   [11]
RP   MYRISTOYLATION AT GLY-2 (ISOFORM IB).
RX   PubMed=2542016; DOI=10.1002/j.1460-2075.1989.tb03397.x;
RA   Jackson P., Baltimore D.;
RT   "N-terminal mutations activate the leukemogenic potential of the
RT   myristoylated form of c-abl.";
RL   EMBO J. 8:449-456(1989).
RN   [12]
RP   DOMAIN, AND DNA-BINDING.
RX   PubMed=2183353; DOI=10.1126/science.2183353;
RA   Kipreos E.T., Wang J.Y.;
RT   "Differential phosphorylation of c-Abl in cell cycle determined by cdc2
RT   kinase and phosphatase activity.";
RL   Science 248:217-220(1990).
RN   [13]
RP   FUNCTION.
RX   PubMed=9037071; DOI=10.1073/pnas.94.4.1437;
RA   Yuan Z.M., Huang Y., Ishiko T., Kharbanda S., Weichselbaum R., Kufe D.;
RT   "Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1437-1440(1997).
RN   [14]
RP   INTERACTION WITH RIN1, AND FUNCTION.
RX   PubMed=9144171; DOI=10.1073/pnas.94.10.4954;
RA   Han L., Wong D., Dhaka A., Afar D.E.H., White M., Xie W., Herschman H.,
RA   Witte O., Colicelli J.;
RT   "Protein binding and signaling properties of RIN1 suggest a unique effector
RT   function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4954-4959(1997).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH RAD51.
RX   PubMed=9461559; DOI=10.1074/jbc.273.7.3799;
RA   Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kharbanda S.,
RA   Wang R., Sung P., Shinohara A., Weichselbaum R., Kufe D.;
RT   "Regulation of Rad51 function by c-Abl in response to DNA damage.";
RL   J. Biol. Chem. 273:3799-3802(1998).
RN   [16]
RP   INTERACTION WITH INPPL1.
RX   PubMed=10194451;
RA   Wisniewski D., Strife A., Swendeman S., Erdjument-Bromage H., Geromanos S.,
RA   Kavanaugh W.M., Tempst P., Clarkson B.;
RT   "A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase (SHIP2) is constitutively tyrosine phosphorylated and
RT   associated with src homologous and collagen gene (SHC) in chronic
RT   myelogenous leukemia progenitor cells.";
RL   Blood 93:2707-2720(1999).
RN   [17]
RP   FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH TP73.
RX   PubMed=10391250; DOI=10.1038/21697;
RA   Agami R., Blandino G., Oren M., Shaul Y.;
RT   "Interaction of c-Abl and p73alpha and their collaboration to induce
RT   apoptosis.";
RL   Nature 399:809-813(1999).
RN   [18]
RP   DNA-BINDING.
RX   PubMed=10325413; DOI=10.1093/nar/27.11.2265;
RA   David-Cordonnier M.H., Payet D., D'Halluin J.C., Waring M.J., Travers A.A.,
RA   Bailly C.;
RT   "The DNA-binding domain of human c-Abl tyrosine kinase promotes the
RT   interaction of a HMG chromosomal protein with DNA.";
RL   Nucleic Acids Res. 27:2265-2270(1999).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=11114745; DOI=10.1038/sj.onc.1203878;
RA   Wang J.Y.;
RT   "Regulation of cell death by the Abl tyrosine kinase.";
RL   Oncogene 19:5643-5650(2000).
RN   [20]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3 domain
RT   containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin
RT   signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH RAD52.
RX   PubMed=12379650; DOI=10.1074/jbc.m208151200;
RA   Kitao H., Yuan Z.M.;
RT   "Regulation of ionizing radiation-induced Rad52 nuclear foci formation by
RT   c-Abl-mediated phosphorylation.";
RL   J. Biol. Chem. 277:48944-48948(2002).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH RAD9A.
RX   PubMed=11971963; DOI=10.1128/mcb.22.10.3292-3300.2002;
RA   Yoshida K., Komatsu K., Wang H.-G., Kufe D.;
RT   "c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 22:3292-3300(2002).
RN   [23]
RP   UBIQUITINATION.
RX   PubMed=12475393; DOI=10.1042/bj20021539;
RA   Soubeyran P., Barac A., Szymkiewicz I., Dikic I.;
RT   "Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl.";
RL   Biochem. J. 370:29-34(2003).
RN   [24]
RP   FUNCTION.
RX   PubMed=12531427; DOI=10.1016/s0898-6568(02)00090-6;
RA   Sanguinetti A.R., Mastick C.C.;
RT   "c-Abl is required for oxidative stress-induced phosphorylation of
RT   caveolin-1 on tyrosine 14.";
RL   Cell. Signal. 15:289-298(2003).
RN   [25]
RP   FUNCTION.
RX   PubMed=12672821; DOI=10.1074/jbc.m301447200;
RA   Tani K., Sato S., Sukezane T., Kojima H., Hirose H., Hanafusa H.,
RA   Shishido T.;
RT   "Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian
RT   enabled (Mena) by c-Abl kinase.";
RL   J. Biol. Chem. 278:21685-21692(2003).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=12775773; DOI=10.1242/jcs.00622;
RA   Woodring P.J., Hunter T., Wang J.Y.;
RT   "Regulation of F-actin-dependent processes by the Abl family of tyrosine
RT   kinases.";
RL   J. Cell Sci. 116:2613-2626(2003).
RN   [27]
RP   INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster region
RT   protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent
RT   manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [28]
RP   FUNCTION.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation sites
RT   within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [29]
RP   FUNCTION.
RX   PubMed=15031292; DOI=10.1074/jbc.m311479200;
RA   Perkinton M.S., Standen C.L., Lau K.F., Kesavapany S., Byers H.L., Ward M.,
RA   McLoughlin D.M., Miller C.C.;
RT   "The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to
RT   stimulate Fe65/amyloid precursor protein nuclear signaling.";
RL   J. Biol. Chem. 279:22084-22091(2004).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=15686624; DOI=10.1038/sj.cr.7290261;
RA   Shaul Y., Ben-Yehoyada M.;
RT   "Role of c-Abl in the DNA damage stress response.";
RL   Cell Res. 15:33-35(2005).
RN   [31]
RP   FUNCTION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-
RT   cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH CASP9.
RX   PubMed=15657060; DOI=10.1074/jbc.m413787200;
RA   Raina D., Pandey P., Ahmad R., Bharti A., Ren J., Kharbanda S.,
RA   Weichselbaum R., Kufe D.;
RT   "c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic
RT   response to DNA damage.";
RL   J. Biol. Chem. 280:11147-11151(2005).
RN   [33]
RP   INTERACTION WITH YWHAB; YWHAE; YWHAG; YWHAH; SFN AND YWHAZ, PHOSPHORYLATION
RP   AT THR-735, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF THR-735.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-
RT   Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [35]
RP   ACETYLATION AT LYS-711, AND SUBCELLULAR LOCATION.
RX   PubMed=16648821; DOI=10.1038/sj.embor.7400700;
RA   di Bari M.G., Ciuffini L., Mingardi M., Testi R., Soddu S., Barila D.;
RT   "c-Abl acetylation by histone acetyltransferases regulates its nuclear-
RT   cytoplasmic localization.";
RL   EMBO Rep. 7:727-733(2006).
RN   [36]
RP   PHOSPHORYLATION AT TYR-70; TYR-115; TYR-128; TYR-139; TYR-172; TYR-185
RP   TYR-215; TYR-226 AND TYR-393, INTERACTION WITH HCK; LYN AND FYN, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16912036; DOI=10.1074/jbc.m605902200;
RA   Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J.,
RA   Hochrein J.M., Engen J.R., Smithgall T.E.;
RT   "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate
RT   Bcr-Abl transforming activity.";
RL   J. Biol. Chem. 281:30907-30916(2006).
RN   [37]
RP   FUNCTION.
RX   PubMed=16943190; DOI=10.1074/jbc.m603126200;
RA   Tanos B., Pendergast A.M.;
RT   "Abl tyrosine kinase regulates endocytosis of the epidermal growth factor
RT   receptor.";
RL   J. Biol. Chem. 281:32714-32723(2006).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q., Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit
RT   PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [39]
RP   FUNCTION.
RX   PubMed=17306540; DOI=10.1016/j.cub.2007.01.057;
RA   Boyle S.N., Michaud G.A., Schweitzer B., Predki P.F., Koleske A.J.;
RT   "A critical role for cortactin phosphorylation by Abl-family kinases in
RT   PDGF-induced dorsal-wave formation.";
RL   Curr. Biol. 17:445-451(2007).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH WASF3.
RX   PubMed=17623672; DOI=10.1074/jbc.m701484200;
RA   Sossey-Alaoui K., Li X., Cowell J.K.;
RT   "c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia
RT   formation and cell migration.";
RL   J. Biol. Chem. 282:26257-26265(2007).
RN   [41]
RP   PHOSPHORYLATION AT SER-618 AND SER-619, AND INTERACTION WITH ABI2 AND CRK.
RX   PubMed=18161990; DOI=10.1021/bi701533j;
RA   Jung J.H., Pendergast A.M., Zipfel P.A., Traugh J.A.;
RT   "Phosphorylation of c-Abl by protein kinase Pak2 regulates differential
RT   binding of ABI2 and CRK.";
RL   Biochemistry 47:1094-1104(2008).
RN   [42]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=18328268; DOI=10.1016/j.bbamcr.2008.01.028;
RA   Xiong X., Cui P., Hossain S., Xu R., Warner B., Guo X., An X.,
RA   Debnath A.K., Cowburn D., Kotula L.;
RT   "Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by
RT   phosphopeptides derived from Abi1/Hssh3bp1.";
RL   Biochim. Biophys. Acta 1783:737-747(2008).
RN   [43]
RP   FUNCTION.
RX   PubMed=18945674; DOI=10.1074/jbc.m804543200;
RA   Yogalingam G., Pendergast A.M.;
RT   "Abl kinases regulate autophagy by promoting the trafficking and function
RT   of lysosomal components.";
RL   J. Biol. Chem. 283:35941-35953(2008).
RN   [44]
RP   PHOSPHORYLATION AT TYR-70, AND INTERACTION WITH ABI1.
RX   PubMed=18775435; DOI=10.1016/j.jmb.2008.08.040;
RA   Chen S., O'Reilly L.P., Smithgall T.E., Engen J.R.;
RT   "Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory
RT   interactions within the c-Abl kinase core.";
RL   J. Mol. Biol. 383:414-423(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-569; SER-659;
RP   THR-814; THR-844 AND SER-977, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; THR-852 AND SER-917, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [47]
RP   REVIEW ON FUNCTION.
RX   PubMed=18182299; DOI=10.1016/j.tibs.2007.10.006;
RA   Backert S., Feller S.M., Wessler S.;
RT   "Emerging roles of Abl family tyrosine kinases in microbial pathogenesis.";
RL   Trends Biochem. Sci. 33:80-90(2008).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [49]
RP   FUNCTION.
RX   PubMed=19891780; DOI=10.1186/1471-2121-10-80;
RA   Fernow I., Tomasovic A., Siehoff-Icking A., Tikkanen R.;
RT   "Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src
RT   kinases.";
RL   BMC Cell Biol. 10:80-80(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [51]
RP   IDENTIFICATION IN A COMPLEX WITH UNC119; ABL2 AND CRK.
RX   PubMed=19381274; DOI=10.1371/journal.pone.0005211;
RA   Vepachedu R., Karim Z., Patel O., Goplen N., Alam R.;
RT   "Unc119 protects from Shigella infection by inhibiting the Abl family
RT   kinases.";
RL   PLoS ONE 4:E5211-E5211(2009).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-569, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [53]
RP   FUNCTION.
RX   PubMed=20417104; DOI=10.1016/j.cub.2010.03.048;
RA   Michael M., Vehlow A., Navarro C., Krause M.;
RT   "c-Abl, Lamellipodin, and Ena/VASP proteins cooperate in dorsal ruffling of
RT   fibroblasts and axonal morphogenesis.";
RL   Curr. Biol. 20:783-791(2010).
RN   [54]
RP   INTERACTION WITH MYLK AND CTTN.
RX   PubMed=20861316; DOI=10.1091/mbc.e09-10-0876;
RA   Dudek S.M., Chiang E.T., Camp S.M., Guo Y., Zhao J., Brown M.E.,
RA   Singleton P.A., Wang L., Desai A., Arce F.T., Lal R., Van Eyk J.E.,
RA   Imam S.Z., Garcia J.G.N.;
RT   "Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to
RT   regulate endothelial barrier function.";
RL   Mol. Biol. Cell 21:4042-4056(2010).
RN   [55]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=20841568; DOI=10.1126/scisignal.3139re6;
RA   Colicelli J.;
RT   "ABL tyrosine kinases: evolution of function, regulation, and
RT   specificity.";
RL   Sci. Signal. 3:RE6-RE6(2010).
RN   [56]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [57]
RP   INTERACTION WITH STX17.
RX   PubMed=23006999; DOI=10.1016/j.bbamcr.2012.09.003;
RA   Muppirala M., Gupta V., Swarup G.;
RT   "Tyrosine phosphorylation of a SNARE protein, Syntaxin 17: Implications for
RT   membrane trafficking in the early secretory pathway.";
RL   Biochim. Biophys. Acta 1823:2109-2119(2012).
RN   [58]
RP   FUNCTION, AND INTERACTION WITH NEDD9.
RX   PubMed=22810897; DOI=10.1126/scisignal.2002632;
RA   Gu J.J., Lavau C.P., Pugacheva E., Soderblom E.J., Moseley M.A.,
RA   Pendergast A.M.;
RT   "Abl family kinases modulate T cell-mediated inflammation and chemokine-
RT   induced migration through the adaptor HEF1 and the GTPase Rap1.";
RL   Sci. Signal. 5:ra51-ra51(2012).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-253; TYR-257; TYR-413;
RP   SER-559; SER-569; SER-620; SER-683; SER-718; THR-751; THR-781; THR-823;
RP   THR-844; THR-852; SER-855 AND SER-917, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [61]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=28428613; DOI=10.1038/s41598-017-00800-w;
RA   Cobbaut M., Derua R., Doeppler H., Lou H.J., Vandoninck S., Storz P.,
RA   Turk B.E., Seufferlein T., Waelkens E., Janssens V., Van Lint J.;
RT   "Differential regulation of PKD isoforms in oxidative stress conditions
RT   through phosphorylation of a conserved Tyr in the P+1 loop.";
RL   Sci. Rep. 7:887-887(2017).
RN   [62]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1505033; DOI=10.1016/0092-8674(92)90437-h;
RA   Overduin M., Rios C.B., Mayer B.J., Baltimore D., Cowburn D.;
RT   "Three-dimensional solution structure of the src homology 2 domain of c-
RT   abl.";
RL   Cell 70:697-704(1992).
RN   [63]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1281542; DOI=10.1073/pnas.89.24.11673;
RA   Overduin M., Mayer B.J., Rios C.B., Baltimore D., Cowburn D.;
RT   "Secondary structure of Src homology 2 domain of c-Abl by heteronuclear NMR
RT   spectroscopy in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11673-11677(1992).
RN   [64]
RP   3D-STRUCTURE MODELING OF SH3 DOMAIN.
RX   PubMed=7892170; DOI=10.1002/prot.340200302;
RA   Pisabarro M.T., Ortiz A.R., Serrano L., Wade R.C.;
RT   "Homology modeling of the Abl-SH3 domain.";
RL   Proteins 20:203-215(1994).
RN   [65]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=8590002; DOI=10.1016/s0969-2126(01)00243-x;
RA   Gosser Y.Q., Zheng J., Overduin M., Mayer B.J., Cowburn D.;
RT   "The solution structure of Abl SH3, and its relationship to SH2 in the
RT   SH(32) construct.";
RL   Structure 3:1075-1086(1995).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 64-121.
RX   PubMed=9698566; DOI=10.1006/jmbi.1998.1932;
RA   Pisabarro M.T., Serrano L., Wilmanns M.;
RT   "Crystal structure of the abl-SH3 domain complexed with a designed high-
RT   affinity peptide ligand: implications for SH3-ligand interactions.";
RL   J. Mol. Biol. 281:513-521(1998).
RN   [67]
RP   STRUCTURE BY NMR OF 62-122 IN COMPLEX WITH CRK.
RX   PubMed=12384576; DOI=10.1073/pnas.212518799;
RA   Donaldson L.W., Gish G., Pawson T., Kay L.E., Forman-Kay J.D.;
RT   "Structure of a regulatory complex involving the Abl SH3 domain, the Crk
RT   SH2 domain, and a Crk-derived phosphopeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14053-14058(2002).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (3.42 ANGSTROMS) OF 27-512, MYRISTOYLATION AT GLY-2
RP   (ISOFORM IB), ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12654251; DOI=10.1016/s0092-8674(03)00194-6;
RA   Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W.,
RA   Clarkson B., Superti-Furga G., Kuriyan J.;
RT   "Structural basis for the autoinhibition of c-Abl tyrosine kinase.";
RL   Cell 112:859-871(2003).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 229-513 OF MUTANT PRO-396 IN
RP   COMPLEX WITH INHIBITOR VX-680, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=16424036; DOI=10.1158/0008-5472.can-05-2788;
RA   Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V.,
RA   Biggs W.H. III, Treiber D.K., Patel H.K., Zarrinkar P.P., Lockhart D.J.,
RA   Sawyers C.L., Kuriyan J.;
RT   "Structure of the kinase domain of an imatinib-resistant Abl mutant in
RT   complex with the Aurora kinase inhibitor VX-680.";
RL   Cancer Res. 66:1007-1014(2006).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-512, IDENTIFICATION BY MASS
RP   SPECTROMETRY, MYRISTOYLATION AT GLY-2 (ISOFORM IB), PHOSPHORYLATION AT
RP   SER-50, AUTOINHIBITORY MECHANISM, AND ACTIVITY REGULATION.
RX   PubMed=16543148; DOI=10.1016/j.molcel.2006.01.035;
RA   Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I.,
RA   Superti-Furga G., Kuriyan J.;
RT   "Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl
RT   tyrosine kinase.";
RL   Mol. Cell 21:787-798(2006).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 229-512 IN COMPLEXES WITH
RP   ATP-PEPTIDE CONJUGATE, AND CONFORMATION CHANGES DURING ACTIVATION.
RX   PubMed=16640460; DOI=10.1371/journal.pbio.0040144;
RA   Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M.,
RA   Cole P.A., Kuriyan J.;
RT   "A Src-like inactive conformation in the abl tyrosine kinase domain.";
RL   PLoS Biol. 4:E144-E144(2006).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 229-500 IN COMPLEXES WITH IMATINIB
RP   AND WITH THE INHIBITORS NVP-AEG082; NVP-AFN941; NVP-AFG210 AND PD180970.
RX   PubMed=17164530; DOI=10.1107/s0907444906047287;
RA   Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P., Liebetanz J.,
RA   Rummel G., Rheinberger P., Centeleghe M., Fabbro D., Manley P.W.;
RT   "Structural biology contributions to the discovery of drugs to treat
RT   chronic myelogenous leukaemia.";
RL   Acta Crystallogr. D 63:80-93(2007).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 64-121 OF MUTANT ALA-114 IN
RP   COMPLEX WITH PROLINE-RICH PEPTIDE.
RX   PubMed=17452790; DOI=10.1107/s0907444907011109;
RA   Camara-Artigas A., Palencia A., Martinez J.C., Luque I., Gavira J.A.,
RA   Garcia-Ruiz J.M.;
RT   "Crystallization by capillary counter-diffusion and structure determination
RT   of the N114A mutant of the SH3 domain of Abl tyrosine kinase complexed with
RT   a high-affinity peptide ligand.";
RL   Acta Crystallogr. D 63:646-652(2007).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 60-121 IN COMPLEX WITH
RP   PROLINE-RICH PEPTIDE P41.
RX   PubMed=19906645; DOI=10.1074/jbc.m109.048033;
RA   Palencia A., Camara-Artigas A., Pisabarro M.T., Martinez J.C., Luque I.;
RT   "Role of interfacial water molecules in proline-rich ligand recognition by
RT   the Src homology 3 domain of Abl.";
RL   J. Biol. Chem. 285:2823-2833(2010).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 121-232 IN COMPLEX WITH ANTIBODY
RP   MIMIC HA4, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20357770; DOI=10.1038/nsmb.1793;
RA   Wojcik J., Hantschel O., Grebien F., Kaupe I., Bennett K.L., Barkinge J.,
RA   Jones R.B., Koide A., Superti-Furga G., Koide S.;
RT   "A potent and highly specific FN3 monobody inhibitor of the Abl SH2
RT   domain.";
RL   Nat. Struct. Mol. Biol. 17:519-527(2010).
RN   [76]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH NUP214.
RX   PubMed=15361874; DOI=10.1038/ng1425;
RA   Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R.,
RA   Vermeesch J.R., Stul M., Dutta B., Boeckx N., Bosly A., Heimann P.,
RA   Uyttebroeck A., Mentens N., Somers R., MacLeod R.A., Drexler H.G.,
RA   Look A.T., Gilliland D.G., Michaux L., Vandenberghe P., Wlodarska I.,
RA   Marynen P., Hagemeijer A.;
RT   "Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute
RT   lymphoblastic leukemia.";
RL   Nat. Genet. 36:1084-1089(2004).
RN   [77]
RP   VARIANTS GLY-47; LYS-166; VAL-706; LEU-810 AND LEU-972.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [78]
RP   INVOLVEMENT IN CHDSKM, VARIANTS CHDSKM CYS-226 AND THR-337, AND
RP   CHARACTERIZATION OF VARIANTS CHDSKM CYS-226 AND THR-337.
RX   PubMed=28288113; DOI=10.1038/ng.3815;
RA   Wang X., Charng W.L., Chen C.A., Rosenfeld J.A., Al Shamsi A.,
RA   Al-Gazali L., McGuire M., Mew N.A., Arnold G.L., Qu C., Ding Y.,
RA   Muzny D.M., Gibbs R.A., Eng C.M., Walkiewicz M., Xia F., Plon S.E.,
RA   Lupski J.R., Schaaf C.P., Yang Y.;
RT   "Germline mutations in ABL1 cause an autosomal dominant syndrome
RT   characterized by congenital heart defects and skeletal malformations.";
RL   Nat. Genet. 49:613-617(2017).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays a role in
CC       many key processes linked to cell growth and survival such as
CC       cytoskeleton remodeling in response to extracellular stimuli, cell
CC       motility and adhesion, receptor endocytosis, autophagy, DNA damage
CC       response and apoptosis. Coordinates actin remodeling through tyrosine
CC       phosphorylation of proteins controlling cytoskeleton dynamics like
CC       WASF3 (involved in branch formation); ANXA1 (involved in membrane
CC       anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling);
CC       or MAPT and PXN (microtubule-binding proteins). Phosphorylation of
CC       WASF3 is critical for the stimulation of lamellipodia formation and
CC       cell migration. Involved in the regulation of cell adhesion and
CC       motility through phosphorylation of key regulators of these processes
CC       such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 (PubMed:22810897).
CC       Phosphorylates multiple receptor tyrosine kinases and more particularly
CC       promotes endocytosis of EGFR, facilitates the formation of
CC       neuromuscular synapses through MUSK, inhibits PDGFRB-mediated
CC       chemotaxis and modulates the endocytosis of activated B-cell receptor
CC       complexes. Other substrates which are involved in endocytosis
CC       regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates
CC       the CBL family of ubiquitin ligases that drive receptor down-regulation
CC       and actin remodeling. Phosphorylation of CBL leads to increased EGFR
CC       stability. Involved in late-stage autophagy by regulating positively
CC       the trafficking and function of lysosomal components. ABL1 targets to
CC       mitochondria in response to oxidative stress and thereby mediates
CC       mitochondrial dysfunction and cell death. In response to oxidative
CC       stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'
CC       (PubMed:28428613). ABL1 is also translocated in the nucleus where it
CC       has DNA-binding activity and is involved in DNA-damage response and
CC       apoptosis. Many substrates are known mediators of DNA repair: DDB1,
CC       DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the
CC       proapoptotic pathway when the DNA damage is too severe to be repaired.
CC       Phosphorylates TP73, a primary regulator for this type of damage-
CC       induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and
CC       regulates its processing in the apoptotic response to DNA damage.
CC       Phosphorylates PSMA7 that leads to an inhibition of proteasomal
CC       activity and cell cycle transition blocks. ABL1 acts also as a
CC       regulator of multiple pathological signaling cascades during infection.
CC       Several known tyrosine-phosphorylated microbial proteins have been
CC       identified as ABL1 substrates. This is the case of A36R of Vaccinia
CC       virus, Tir (translocated intimin receptor) of pathogenic E.coli and
CC       possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori,
CC       or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum.
CC       Pathogens can highjack ABL1 kinase signaling to reorganize the host
CC       actin cytoskeleton for multiple purposes, like facilitating
CC       intracellular movement and host cell exit. Finally, functions as its
CC       own regulator through autocatalytic activity as well as through
CC       phosphorylation of its inhibitor, ABI1. Regulates T-cell
CC       differentiation in a TBX21-dependent manner (By similarity). Positively
CC       regulates chemokine-mediated T-cell migration, polarization, and homing
CC       to lymph nodes and immune-challenged tissues, potentially via
CC       activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21
CC       on tyrosine residues leading to an enhancement of its transcriptional
CC       activator activity (By similarity). {ECO:0000250|UniProtKB:P00520,
CC       ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:11971963,
CC       ECO:0000269|PubMed:12379650, ECO:0000269|PubMed:12531427,
CC       ECO:0000269|PubMed:12672821, ECO:0000269|PubMed:15031292,
CC       ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:15657060,
CC       ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16424036,
CC       ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:16943190,
CC       ECO:0000269|PubMed:17306540, ECO:0000269|PubMed:17623672,
CC       ECO:0000269|PubMed:18328268, ECO:0000269|PubMed:18945674,
CC       ECO:0000269|PubMed:19891780, ECO:0000269|PubMed:20357770,
CC       ECO:0000269|PubMed:20417104, ECO:0000269|PubMed:22810897,
CC       ECO:0000269|PubMed:28428613, ECO:0000269|PubMed:9037071,
CC       ECO:0000269|PubMed:9144171, ECO:0000269|PubMed:9461559}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:28428613};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P00520};
CC   -!- ACTIVITY REGULATION: Stabilized in the inactive form by an association
CC       between the SH3 domain and the SH2-TK linker region, interactions of
CC       the N-terminal cap, and contributions from an N-terminal myristoyl
CC       group and phospholipids. Activated by autophosphorylation as well as by
CC       SRC-family kinase-mediated phosphorylation. Activated by RIN1 binding
CC       to the SH2 and SH3 domains. Also stimulated by cell death inducers and
CC       DNA-damage. Phosphatidylinositol 4,5-bisphosphate (PIP2), a highly
CC       abundant phosphoinositide known to regulate cytoskeletal and membrane
CC       proteins, inhibits also the tyrosine kinase activity (By similarity).
CC       Activated by 5-(1,3-diaryl-1H-pyrazol-4-yl)hydantoin, 5-[3-(4-
CC       fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-2,4-imidazolidinedione (DPH)
CC       (PubMed:28428613). Inhibited by ABI1, whose activity is controlled by
CC       ABL1 itself through tyrosine phosphorylation. Also inhibited by
CC       imatinib mesylate (Gleevec) which is used for the treatment of chronic
CC       myeloid leukemia (CML), and by VX-680, an inhibitor that acts also on
CC       imatinib-resistant mutants (PubMed:28428613). {ECO:0000250,
CC       ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:12654251,
CC       ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16543148,
CC       ECO:0000269|PubMed:18328268, ECO:0000269|PubMed:28428613}.
CC   -!- SUBUNIT: Interacts with SORBS1 following insulin stimulation. Found in
CC       a trimolecular complex containing CDK5 and CABLES1. Interacts with
CC       CABLES1 and PSTPIP1. Interacts with ZDHHC16, ITGB1 and HCK (By
CC       similarity). Interacts with STX17; probably phosphorylates STX17.
CC       Interacts with INPPL1/SHIP2. Interacts with the 14-3-3 proteins, YWHAB,
CC       YWHAE, YWHAG, YWHAH, SFN and YWHAZ; the interaction with 14-3-3
CC       proteins requires phosphorylation on Thr-735 and, sequesters ABL1 into
CC       the cytoplasm. Interacts with ABI1, ABI2, BCR, CRK, FGR, FYN, HCK, LYN,
CC       PSMA7 RAD9A, RAD51, RAD52, TP73 and WASF3. A complex made of ABL1, CTTN
CC       and MYLK regulates cortical actin-based cytoskeletal rearrangement
CC       critical to sphingosine 1-phosphate (S1P)-mediated endothelial cell
CC       (EC) barrier enhancement. Interacts (via SH3 domain) with CASP9; the
CC       interaction is direct and increases in the response of cells to
CC       genotoxic stress and ABL1/c-Abl activation. Found in a complex with
CC       ABL1, ABL2, CRK and UNC119; leading to the inhibition of CRK
CC       phosphorylation by ABL kinases. Interacts with TBX21 (By similarity).
CC       Interacts with NEDD9/HEF1; interaction is induced by CXCL12 promotion
CC       of ABL-mediated phosphorylation of NEDD9/HEF1 (PubMed:22810897).
CC       {ECO:0000250|UniProtKB:P00520, ECO:0000269|PubMed:10194451,
CC       ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:11374898,
CC       ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12379650,
CC       ECO:0000269|PubMed:12384576, ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:15657060, ECO:0000269|PubMed:15696159,
CC       ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16678104,
CC       ECO:0000269|PubMed:16912036, ECO:0000269|PubMed:17452790,
CC       ECO:0000269|PubMed:17623672, ECO:0000269|PubMed:18161990,
CC       ECO:0000269|PubMed:18775435, ECO:0000269|PubMed:19381274,
CC       ECO:0000269|PubMed:19906645, ECO:0000269|PubMed:20357770,
CC       ECO:0000269|PubMed:20861316, ECO:0000269|PubMed:22810897,
CC       ECO:0000269|PubMed:23006999, ECO:0000269|PubMed:9144171,
CC       ECO:0000269|PubMed:9461559}.
CC   -!- INTERACTION:
CC       P00519; Q8IZP0: ABI1; NbExp=11; IntAct=EBI-375543, EBI-375446;
CC       P00519; Q9NYB9: ABI2; NbExp=2; IntAct=EBI-375543, EBI-743598;
CC       P00519; O14672: ADAM10; NbExp=2; IntAct=EBI-375543, EBI-1536151;
CC       P00519; P10275: AR; NbExp=2; IntAct=EBI-375543, EBI-608057;
CC       P00519; Q13315: ATM; NbExp=4; IntAct=EBI-375543, EBI-495465;
CC       P00519; Q4KMG0: CDON; NbExp=2; IntAct=EBI-375543, EBI-7016840;
CC       P00519; P46108: CRK; NbExp=4; IntAct=EBI-375543, EBI-886;
CC       P00519; P46109: CRKL; NbExp=3; IntAct=EBI-375543, EBI-910;
CC       P00519; P35222: CTNNB1; NbExp=2; IntAct=EBI-375543, EBI-491549;
CC       P00519; P00533: EGFR; NbExp=3; IntAct=EBI-375543, EBI-297353;
CC       P00519; P04626: ERBB2; NbExp=2; IntAct=EBI-375543, EBI-641062;
CC       P00519; Q03468: ERCC6; NbExp=8; IntAct=EBI-375543, EBI-295284;
CC       P00519; Q14315: FLNC; NbExp=2; IntAct=EBI-375543, EBI-489954;
CC       P00519; P36888: FLT3; NbExp=2; IntAct=EBI-375543, EBI-3946257;
CC       P00519; P05107: ITGB2; NbExp=4; IntAct=EBI-375543, EBI-300173;
CC       P00519; P10721: KIT; NbExp=2; IntAct=EBI-375543, EBI-1379503;
CC       P00519; Q38SD2: LRRK1; NbExp=3; IntAct=EBI-375543, EBI-1050422;
CC       P00519; Q92918: MAP4K1; NbExp=3; IntAct=EBI-375543, EBI-881;
CC       P00519; Q7Z434: MAVS; NbExp=6; IntAct=EBI-375543, EBI-995373;
CC       P00519; O43196: MSH5; NbExp=10; IntAct=EBI-375543, EBI-6092730;
CC       P00519; P15941: MUC1; NbExp=8; IntAct=EBI-375543, EBI-2804728;
CC       P00519; P16333: NCK1; NbExp=2; IntAct=EBI-375543, EBI-389883;
CC       P00519; O43900: PRICKLE3; NbExp=2; IntAct=EBI-375543, EBI-1751761;
CC       P00519; Q13905: RAPGEF1; NbExp=4; IntAct=EBI-375543, EBI-976876;
CC       P00519; Q86UR5: RIMS1; NbExp=2; IntAct=EBI-375543, EBI-1043236;
CC       P00519; Q13671: RIN1; NbExp=4; IntAct=EBI-375543, EBI-366017;
CC       P00519; P31947: SFN; NbExp=2; IntAct=EBI-375543, EBI-476295;
CC       P00519; Q15464: SHB; NbExp=5; IntAct=EBI-375543, EBI-4402156;
CC       P00519; O75751: SLC22A3; NbExp=2; IntAct=EBI-375543, EBI-1752674;
CC       P00519; P37840: SNCA; NbExp=3; IntAct=EBI-375543, EBI-985879;
CC       P00519; Q9BX66: SORBS1; NbExp=2; IntAct=EBI-375543, EBI-433642;
CC       P00519; O60504-2: SORBS3; NbExp=5; IntAct=EBI-375543, EBI-1222956;
CC       P00519; Q07890: SOS2; NbExp=2; IntAct=EBI-375543, EBI-298181;
CC       P00519; P12931: SRC; NbExp=2; IntAct=EBI-375543, EBI-621482;
CC       P00519; P51692: STAT5B; NbExp=2; IntAct=EBI-375543, EBI-1186119;
CC       P00519; Q9Y4G6: TLN2; NbExp=3; IntAct=EBI-375543, EBI-1220811;
CC       P00519; P11387: TOP1; NbExp=7; IntAct=EBI-375543, EBI-876302;
CC       P00519; P15498: VAV1; NbExp=5; IntAct=EBI-375543, EBI-625518;
CC       P00519; P61981: YWHAG; NbExp=4; IntAct=EBI-375543, EBI-359832;
CC       P00519; P63104: YWHAZ; NbExp=3; IntAct=EBI-375543, EBI-347088;
CC       P00519; O35158: Cdon; Xeno; NbExp=4; IntAct=EBI-375543, EBI-7016767;
CC       P00519-1; P37840: SNCA; NbExp=6; IntAct=EBI-5278159, EBI-985879;
CC       P00519-2; P48165: GJA8; NbExp=3; IntAct=EBI-9254597, EBI-17458373;
CC       P00519-2; Q15323: KRT31; NbExp=3; IntAct=EBI-9254597, EBI-948001;
CC       P00519-2; P37840: SNCA; NbExp=5; IntAct=EBI-9254597, EBI-985879;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Nucleus. Mitochondrion
CC       {ECO:0000250}. Note=Shuttles between the nucleus and cytoplasm
CC       depending on environmental signals. Sequestered into the cytoplasm
CC       through interaction with 14-3-3 proteins. Localizes to mitochondria in
CC       response to oxidative stress (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform IB]: Nucleus membrane; Lipid-anchor.
CC       Note=The myristoylated c-ABL protein is reported to be nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=IA;
CC         IsoId=P00519-1; Sequence=Displayed;
CC       Name=IB;
CC         IsoId=P00519-2; Sequence=VSP_004957;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Acetylated at Lys-711 by EP300 which promotes the cytoplasmic
CC       translocation. {ECO:0000269|PubMed:16648821}.
CC   -!- PTM: Phosphorylation at Tyr-70 by members of the SRC family of kinases
CC       disrupts SH3 domain-based autoinhibitory interactions and
CC       intermolecular associations, such as that with ABI1, and also enhances
CC       kinase activity. Phosphorylation at Tyr-226 and Tyr-393 correlate with
CC       increased activity. DNA damage-induced activation of ABL1 requires the
CC       function of ATM and Ser-446 phosphorylation (By similarity).
CC       Phosphorylation at Ser-569 has been attributed to a CDC2-associated
CC       kinase and is coupled to cell division (By similarity). Phosphorylation
CC       at Ser-618 and Ser-619 by PAK2 increases binding to CRK and reduces
CC       binding to ABI1. Phosphorylation on Thr-735 is required for binding 14-
CC       3-3 proteins for cytoplasmic translocation. Phosphorylated by PRKDC (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated. Polyubiquitination of ABL1 leads to
CC       degradation. {ECO:0000269|PubMed:12475393}.
CC   -!- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal
CC       myeloproliferative disorder of a pluripotent stem cell with a specific
CC       cytogenetic abnormality, the Philadelphia chromosome (Ph), involving
CC       myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-
CC       lymphoid cells, but not marrow fibroblasts. Note=The gene represented
CC       in this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Note=A chromosomal aberration involving ABL1 has been found in
CC       patients with chronic myeloid leukemia. Translocation t(9;22)(q34;q11)
CC       with BCR. The translocation produces a BCR-ABL found also in acute
CC       myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
CC       {ECO:0000269|PubMed:3021337}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ABL1 is found in a
CC       form of acute lymphoblastic leukemia (PubMed:15361874). Translocation
CC       t(9;9)(q34;q34) with NUP214 (PubMed:15361874).
CC       {ECO:0000269|PubMed:15361874}.
CC   -!- DISEASE: Congenital heart defects and skeletal malformations syndrome
CC       (CHDSKM) [MIM:617602]: An autosomal dominant disorder characterized by
CC       congenital heart disease with atrial and ventricular septal defects,
CC       variable skeletal abnormalities, and failure to thrive. Skeletal
CC       defects include pectus excavatum, scoliosis, and finger contractures.
CC       Some patient exhibit joint laxity. {ECO:0000269|PubMed:28288113}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABLID1.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14752; AAA51561.1; -; mRNA.
DR   EMBL; X16416; CAA34438.1; -; mRNA.
DR   EMBL; U07563; AAB60394.1; -; Genomic_DNA.
DR   EMBL; U07563; AAB60393.1; -; Genomic_DNA.
DR   EMBL; U07561; AAB60393.1; JOINED; Genomic_DNA.
DR   EMBL; DQ145721; AAZ38718.1; -; Genomic_DNA.
DR   EMBL; AL359092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161733; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471090; EAW87948.1; -; Genomic_DNA.
DR   EMBL; BC117451; AAI17452.1; -; mRNA.
DR   EMBL; S69223; AAD14034.1; -; Genomic_DNA.
DR   CCDS; CCDS35165.1; -. [P00519-2]
DR   CCDS; CCDS35166.1; -. [P00519-1]
DR   PIR; S08519; TVHUA.
DR   RefSeq; NP_005148.2; NM_005157.5. [P00519-1]
DR   RefSeq; NP_009297.2; NM_007313.2. [P00519-2]
DR   PDB; 1AB2; NMR; -; A=120-220.
DR   PDB; 1AWO; NMR; -; A=65-119.
DR   PDB; 1BBZ; X-ray; 1.65 A; A/C/E/G=64-121.
DR   PDB; 1JU5; NMR; -; C=62-122.
DR   PDB; 1OPL; X-ray; 3.42 A; A/B=27-512.
DR   PDB; 1ZZP; NMR; -; A=1007-1130.
DR   PDB; 2ABL; X-ray; 2.50 A; A=57-218.
DR   PDB; 2E2B; X-ray; 2.20 A; A/B=229-515.
DR   PDB; 2F4J; X-ray; 1.91 A; A=229-513.
DR   PDB; 2FO0; X-ray; 2.27 A; A=38-512.
DR   PDB; 2G1T; X-ray; 1.80 A; A/B/C/D=229-512.
DR   PDB; 2G2F; X-ray; 2.70 A; A/B=229-512.
DR   PDB; 2G2H; X-ray; 2.00 A; A/B=229-512.
DR   PDB; 2G2I; X-ray; 3.12 A; A/B=229-512.
DR   PDB; 2GQG; X-ray; 2.40 A; A/B=229-500.
DR   PDB; 2HIW; X-ray; 2.20 A; A/B=230-512.
DR   PDB; 2HYY; X-ray; 2.40 A; A/B/C/D=228-500.
DR   PDB; 2HZ0; X-ray; 2.10 A; A/B=228-497.
DR   PDB; 2HZ4; X-ray; 2.80 A; A/B/C=228-500.
DR   PDB; 2HZI; X-ray; 1.70 A; A/B=229-500.
DR   PDB; 2O88; X-ray; 1.75 A; A/B=64-121.
DR   PDB; 2V7A; X-ray; 2.50 A; A/B=229-512.
DR   PDB; 3CS9; X-ray; 2.21 A; A/B/C/D=229-500.
DR   PDB; 3EG0; X-ray; 2.30 A; A=60-121.
DR   PDB; 3EG1; X-ray; 1.85 A; A/B=60-121.
DR   PDB; 3EG2; X-ray; 1.80 A; A=60-121.
DR   PDB; 3EG3; X-ray; 1.40 A; A=60-121.
DR   PDB; 3EGU; X-ray; 2.25 A; A=60-121.
DR   PDB; 3K2M; X-ray; 1.75 A; A/B=121-232.
DR   PDB; 3PYY; X-ray; 1.85 A; A/B=229-512.
DR   PDB; 3QRI; X-ray; 2.10 A; A/B=229-499.
DR   PDB; 3QRJ; X-ray; 1.82 A; A/B=229-499.
DR   PDB; 3QRK; X-ray; 2.30 A; A=229-499.
DR   PDB; 3T04; X-ray; 2.10 A; A=112-232.
DR   PDB; 3UE4; X-ray; 2.42 A; A/B=229-512.
DR   PDB; 3UYO; X-ray; 1.83 A; A=112-232.
DR   PDB; 4J9B; X-ray; 1.70 A; A=60-121.
DR   PDB; 4J9C; X-ray; 1.05 A; A=60-121.
DR   PDB; 4J9D; X-ray; 1.50 A; A/C/E=60-121.
DR   PDB; 4J9E; X-ray; 1.40 A; A/C/E=60-121.
DR   PDB; 4J9F; X-ray; 1.09 A; A/C/E=60-121.
DR   PDB; 4J9G; X-ray; 1.80 A; A/C/E=60-121.
DR   PDB; 4J9H; X-ray; 1.70 A; A/B/C/D/E/F=60-121.
DR   PDB; 4J9I; X-ray; 2.20 A; A/C/E=60-121.
DR   PDB; 4JJB; X-ray; 1.65 A; A=60-121.
DR   PDB; 4JJC; X-ray; 1.60 A; A=60-121.
DR   PDB; 4JJD; X-ray; 1.60 A; A=60-121.
DR   PDB; 4TWP; X-ray; 2.40 A; A/B=233-503.
DR   PDB; 4WA9; X-ray; 2.20 A; A/B=246-512.
DR   PDB; 4XEY; X-ray; 2.89 A; A/B=119-515.
DR   PDB; 4YC8; X-ray; 2.90 A; A/B=229-512.
DR   PDB; 4ZOG; X-ray; 2.30 A; A/B=229-511.
DR   PDB; 5DC0; X-ray; 2.23 A; B=112-232.
DR   PDB; 5DC4; X-ray; 1.48 A; A=112-232.
DR   PDB; 5DC9; X-ray; 1.56 A; A=112-232.
DR   PDB; 5HU9; X-ray; 1.53 A; A=229-500.
DR   PDB; 5MO4; X-ray; 2.17 A; A=27-515.
DR   PDB; 5NP2; X-ray; 1.60 A; A/B=64-120.
DR   PDB; 5OAZ; X-ray; 1.03 A; A/B=60-121.
DR   PDB; 6AMV; NMR; -; A=26-236.
DR   PDB; 6AMW; NMR; -; A=26-236.
DR   PDB; 6BL8; X-ray; 2.50 A; A/B=233-504.
DR   PDB; 6NPE; X-ray; 2.15 A; A/B=229-512.
DR   PDB; 6NPU; X-ray; 2.33 A; A/B=229-512.
DR   PDB; 6NPV; X-ray; 1.86 A; A/B=229-512.
DR   PDB; 6XR6; NMR; -; A=229-515.
DR   PDB; 6XR7; NMR; -; A=229-515.
DR   PDB; 6XRG; NMR; -; A=229-515.
DR   PDB; 7CC2; X-ray; 2.72 A; A/B=229-510.
DR   PDB; 7DT2; X-ray; 2.30 A; A/B=229-510.
DR   PDBsum; 1AB2; -.
DR   PDBsum; 1AWO; -.
DR   PDBsum; 1BBZ; -.
DR   PDBsum; 1JU5; -.
DR   PDBsum; 1OPL; -.
DR   PDBsum; 1ZZP; -.
DR   PDBsum; 2ABL; -.
DR   PDBsum; 2E2B; -.
DR   PDBsum; 2F4J; -.
DR   PDBsum; 2FO0; -.
DR   PDBsum; 2G1T; -.
DR   PDBsum; 2G2F; -.
DR   PDBsum; 2G2H; -.
DR   PDBsum; 2G2I; -.
DR   PDBsum; 2GQG; -.
DR   PDBsum; 2HIW; -.
DR   PDBsum; 2HYY; -.
DR   PDBsum; 2HZ0; -.
DR   PDBsum; 2HZ4; -.
DR   PDBsum; 2HZI; -.
DR   PDBsum; 2O88; -.
DR   PDBsum; 2V7A; -.
DR   PDBsum; 3CS9; -.
DR   PDBsum; 3EG0; -.
DR   PDBsum; 3EG1; -.
DR   PDBsum; 3EG2; -.
DR   PDBsum; 3EG3; -.
DR   PDBsum; 3EGU; -.
DR   PDBsum; 3K2M; -.
DR   PDBsum; 3PYY; -.
DR   PDBsum; 3QRI; -.
DR   PDBsum; 3QRJ; -.
DR   PDBsum; 3QRK; -.
DR   PDBsum; 3T04; -.
DR   PDBsum; 3UE4; -.
DR   PDBsum; 3UYO; -.
DR   PDBsum; 4J9B; -.
DR   PDBsum; 4J9C; -.
DR   PDBsum; 4J9D; -.
DR   PDBsum; 4J9E; -.
DR   PDBsum; 4J9F; -.
DR   PDBsum; 4J9G; -.
DR   PDBsum; 4J9H; -.
DR   PDBsum; 4J9I; -.
DR   PDBsum; 4JJB; -.
DR   PDBsum; 4JJC; -.
DR   PDBsum; 4JJD; -.
DR   PDBsum; 4TWP; -.
DR   PDBsum; 4WA9; -.
DR   PDBsum; 4XEY; -.
DR   PDBsum; 4YC8; -.
DR   PDBsum; 4ZOG; -.
DR   PDBsum; 5DC0; -.
DR   PDBsum; 5DC4; -.
DR   PDBsum; 5DC9; -.
DR   PDBsum; 5HU9; -.
DR   PDBsum; 5MO4; -.
DR   PDBsum; 5NP2; -.
DR   PDBsum; 5OAZ; -.
DR   PDBsum; 6AMV; -.
DR   PDBsum; 6AMW; -.
DR   PDBsum; 6BL8; -.
DR   PDBsum; 6NPE; -.
DR   PDBsum; 6NPU; -.
DR   PDBsum; 6NPV; -.
DR   PDBsum; 6XR6; -.
DR   PDBsum; 6XR7; -.
DR   PDBsum; 6XRG; -.
DR   PDBsum; 7CC2; -.
DR   PDBsum; 7DT2; -.
DR   AlphaFoldDB; P00519; -.
DR   BMRB; P00519; -.
DR   SMR; P00519; -.
DR   BioGRID; 106543; 213.
DR   CORUM; P00519; -.
DR   DIP; DIP-1042N; -.
DR   IntAct; P00519; 248.
DR   MINT; P00519; -.
DR   STRING; 9606.ENSP00000361423; -.
DR   BindingDB; P00519; -.
DR   ChEMBL; CHEMBL1862; -.
DR   DrugBank; DB08043; 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA.
DR   DrugBank; DB08583; 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide.
DR   DrugBank; DB07831; 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE.
DR   DrugBank; DB08350; 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE.
DR   DrugBank; DB12597; Asciminib.
DR   DrugBank; DB00171; ATP.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB13749; Magnesium gluconate.
DR   DrugBank; DB08231; Myristic acid.
DR   DrugBank; DB03878; N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB08339; PD-166326.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB12323; Radotinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB14989; Umbralisib.
DR   DrugBank; DB05184; XL228.
DR   DrugCentral; P00519; -.
DR   GuidetoPHARMACOLOGY; 1923; -.
DR   MoonDB; P00519; Predicted.
DR   GlyGen; P00519; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P00519; -.
DR   PhosphoSitePlus; P00519; -.
DR   BioMuta; ABL1; -.
DR   DMDM; 85681908; -.
DR   CPTAC; CPTAC-1776; -.
DR   CPTAC; CPTAC-1788; -.
DR   EPD; P00519; -.
DR   jPOST; P00519; -.
DR   MassIVE; P00519; -.
DR   MaxQB; P00519; -.
DR   PaxDb; P00519; -.
DR   PeptideAtlas; P00519; -.
DR   PRIDE; P00519; -.
DR   ProteomicsDB; 51259; -. [P00519-1]
DR   ProteomicsDB; 51260; -. [P00519-2]
DR   Antibodypedia; 3637; 2214 antibodies from 43 providers.
DR   DNASU; 25; -.
DR   Ensembl; ENST00000318560.6; ENSP00000323315.5; ENSG00000097007.19. [P00519-1]
DR   Ensembl; ENST00000372348.7; ENSP00000361423.2; ENSG00000097007.19. [P00519-2]
DR   GeneID; 25; -.
DR   KEGG; hsa:25; -.
DR   MANE-Select; ENST00000318560.6; ENSP00000323315.5; NM_005157.6; NP_005148.2.
DR   UCSC; uc004bzv.4; human. [P00519-1]
DR   CTD; 25; -.
DR   DisGeNET; 25; -.
DR   GeneCards; ABL1; -.
DR   HGNC; HGNC:76; ABL1.
DR   HPA; ENSG00000097007; Low tissue specificity.
DR   MalaCards; ABL1; -.
DR   MIM; 189980; gene.
DR   MIM; 608232; phenotype.
DR   MIM; 617602; phenotype.
DR   neXtProt; NX_P00519; -.
DR   OpenTargets; ENSG00000097007; -.
DR   Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2).
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA24413; -.
DR   VEuPathDB; HostDB:ENSG00000097007; -.
DR   eggNOG; KOG4278; Eukaryota.
DR   GeneTree; ENSGT00940000153838; -.
DR   HOGENOM; CLU_002795_0_0_1; -.
DR   InParanoid; P00519; -.
DR   OMA; CPAFLGK; -.
DR   PhylomeDB; P00519; -.
DR   TreeFam; TF105081; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P00519; -.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-428890; Role of ABL in ROBO-SLIT signaling.
DR   Reactome; R-HSA-525793; Myogenesis.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P00519; -.
DR   SIGNOR; P00519; -.
DR   BioGRID-ORCS; 25; 29 hits in 1117 CRISPR screens.
DR   ChiTaRS; ABL1; human.
DR   EvolutionaryTrace; P00519; -.
DR   GeneWiki; ABL_(gene); -.
DR   GenomeRNAi; 25; -.
DR   Pharos; P00519; Tclin.
DR   PRO; PR:P00519; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P00519; protein.
DR   Bgee; ENSG00000097007; Expressed in frontal pole and 194 other tissues.
DR   ExpressionAtlas; P00519; baseline and differential.
DR   Genevisible; P00519; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; ISS:ARUK-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; TAS:ARUK-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IPI:CAFA.
DR   GO; GO:0001726; C:ruffle; IEA:Ensembl.
DR   GO; GO:0051015; F:actin filament binding; IEA:Ensembl.
DR   GO; GO:0003785; F:actin monomer binding; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0070097; F:delta-catenin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; ISS:ARUK-UCL.
DR   GO; GO:0000400; F:four-way junction DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0016301; F:kinase activity; IMP:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0038191; F:neuropilin binding; IPI:BHF-UCL.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; TAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0070064; F:proline-rich region binding; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0043621; F:protein self-association; IPI:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:CAFA.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0019905; F:syntaxin binding; IPI:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ARUK-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0030041; P:actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0050798; P:activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:1990051; P:activation of protein kinase C activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0008306; P:associative learning; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0002322; P:B cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001922; P:B-1 B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0098609; P:cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:1903351; P:cellular response to dopamine; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IEA:Ensembl.
DR   GO; GO:0021587; P:cerebellum morphogenesis; IEA:Ensembl.
DR   GO; GO:1904157; P:DN4 thymocyte differentiation; IEA:Ensembl.
DR   GO; GO:0071103; P:DNA conformation change; IDA:ARUK-UCL.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0043542; P:endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; TAS:UniProtKB.
DR   GO; GO:0030035; P:microspike assembly; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; TAS:ProtInc.
DR   GO; GO:0051882; P:mitochondrial depolarization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; ISS:ARUK-UCL.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:1900275; P:negative regulation of phospholipase C activity; IMP:MGI.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0051444; P:negative regulation of ubiquitin-protein transferase activity; IDA:MGI.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0060563; P:neuroepithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0070997; P:neuron death; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0038189; P:neuropilin signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903210; P:podocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:BHF-UCL.
DR   GO; GO:1904531; P:positive regulation of actin filament binding; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1905555; P:positive regulation of blood vessel branching; IEA:Ensembl.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:MGI.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:1903905; P:positive regulation of establishment of T cell polarity; ISS:UniProtKB.
DR   GO; GO:1903055; P:positive regulation of extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:BHF-UCL.
DR   GO; GO:1901300; P:positive regulation of hydrogen peroxide-mediated programmed cell death; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:1904528; P:positive regulation of microtubule binding; IMP:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IMP:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:BHF-UCL.
DR   GO; GO:2000406; P:positive regulation of T cell migration; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; TAS:ARUK-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:2000096; P:positive regulation of Wnt signaling pathway, planar cell polarity pathway; IEA:Ensembl.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1904518; P:protein localization to cytoplasmic microtubule plus-end; IMP:UniProtKB.
DR   GO; GO:0036211; P:protein modification process; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0030516; P:regulation of axon extension; IMP:UniProtKB.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:ParkinsonsUK-UCL.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:ProtInc.
DR   GO; GO:0030100; P:regulation of endocytosis; TAS:UniProtKB.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0031113; P:regulation of microtubule polymerization; IMP:UniProtKB.
DR   GO; GO:1905244; P:regulation of modification of synaptic structure; ISS:ARUK-UCL.
DR   GO; GO:2001020; P:regulation of response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0045580; P:regulation of T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0071871; P:response to epinephrine; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IGI:MGI.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0002333; P:transitional one stage B cell differentiation; IEA:Ensembl.
DR   CDD; cd09935; SH2_ABL; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   IDEAL; IID00645; -.
DR   InterPro; IPR033221; ABL1.
DR   InterPro; IPR035837; ABL_SH2.
DR   InterPro; IPR015015; F-actin-binding.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR24418:SF162; PTHR24418:SF162; 1.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Autophagy; Cell adhesion; Chromosomal rearrangement; Cytoplasm;
KW   Cytoskeleton; Disease variant; DNA damage; DNA repair; DNA-binding;
KW   Endocytosis; Kinase; Lipoprotein; Magnesium; Manganese; Membrane;
KW   Metal-binding; Mitochondrion; Myristate; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN           1..1130
FT                   /note="Tyrosine-protein kinase ABL1"
FT                   /id="PRO_0000088050"
FT   DOMAIN          61..121
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          127..217
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          242..493
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..60
FT                   /note="CAP"
FT   REGION          518..996
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          869..968
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          953..1130
FT                   /note="F-actin-binding"
FT   MOTIF           381..405
FT                   /note="Kinase activation loop"
FT   MOTIF           605..609
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000255"
FT   MOTIF           709..715
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000255"
FT   MOTIF           762..769
FT                   /note="Nuclear localization signal 3"
FT                   /evidence="ECO:0000255"
FT   MOTIF           1090..1100
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        533..549
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        579..601
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        622..638
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        685..703
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        735..753
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        758..772
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        870..894
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        363
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         248..256
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         271
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         316..322
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   SITE            26..27
FT                   /note="Breakpoint for translocation to form BCR-ABL and
FT                   NUP214-ABL1 fusion proteins"
FT                   /evidence="ECO:0000269|PubMed:15361874,
FT                   ECO:0000269|PubMed:3021337"
FT   MOD_RES         50
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16543148,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332"
FT   MOD_RES         70
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16912036,
FT                   ECO:0000269|PubMed:18775435"
FT   MOD_RES         115
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         128
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         139
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         172
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         185
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         215
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         226
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         229
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42684"
FT   MOD_RES         253
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         257
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         393
FT                   /note="Phosphotyrosine; by autocatalysis and SRC-type Tyr-
FT                   kinases"
FT                   /evidence="ECO:0000269|PubMed:16912036"
FT   MOD_RES         413
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P00520"
FT   MOD_RES         559
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         569
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         618
FT                   /note="Phosphoserine; by PAK2"
FT                   /evidence="ECO:0000269|PubMed:18161990"
FT   MOD_RES         619
FT                   /note="Phosphoserine; by PAK2"
FT                   /evidence="ECO:0000269|PubMed:18161990"
FT   MOD_RES         620
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         659
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         683
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         711
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000269|PubMed:16648821"
FT   MOD_RES         718
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         735
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15696159"
FT   MOD_RES         751
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         781
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         814
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         823
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         844
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         852
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         855
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         917
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         977
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         1..26
FT                   /note="MLEICLKLVGCKSKKGLSSSSSCYLE -> MGQQPGKVLGDQRRPSLPALHF
FT                   IKGAGKKESSRHGGPHCNVFVEH (in isoform IB)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_004957"
FT   VARIANT         47
FT                   /note="R -> G (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032676"
FT   VARIANT         140
FT                   /note="L -> P (in dbSNP:rs1064152)"
FT                   /evidence="ECO:0000269|PubMed:3021337"
FT                   /id="VAR_051692"
FT   VARIANT         166
FT                   /note="R -> K (in a melanoma sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032677"
FT   VARIANT         226
FT                   /note="Y -> C (in CHDSKM; increases kinase activity; no
FT                   effect on protein levels; dbSNP:rs1060499547)"
FT                   /evidence="ECO:0000269|PubMed:28288113"
FT                   /id="VAR_079482"
FT   VARIANT         247
FT                   /note="K -> R (in dbSNP:rs34549764)"
FT                   /id="VAR_051693"
FT   VARIANT         337
FT                   /note="A -> T (in CHDSKM; increases kinase activity; no
FT                   effect on protein levels; dbSNP:rs1060499548)"
FT                   /evidence="ECO:0000269|PubMed:28288113"
FT                   /id="VAR_079483"
FT   VARIANT         706
FT                   /note="G -> V (in dbSNP:rs34634745)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4"
FT                   /id="VAR_025043"
FT   VARIANT         810
FT                   /note="P -> L (in dbSNP:rs2229071)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032678"
FT   VARIANT         852
FT                   /note="T -> P (in dbSNP:rs1588283506)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_025044"
FT   VARIANT         900
FT                   /note="P -> S (in dbSNP:rs35266696)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_025045"
FT   VARIANT         968
FT                   /note="S -> P (in dbSNP:rs1064165)"
FT                   /id="VAR_051694"
FT   VARIANT         972
FT                   /note="S -> L (in dbSNP:rs2229067)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4"
FT                   /id="VAR_025046"
FT   MUTAGEN         735
FT                   /note="T->A: Abolishes phosphorylation. Loss of binding
FT                   YWHAS and YWHAZ. Localizes to the nucleus. No effect on
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15696159"
FT   CONFLICT        159
FT                   /note="G -> S (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        424..425
FT                   /note="AF -> GK (in Ref. 9)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        445
FT                   /note="L -> R (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        459
FT                   /note="E -> K (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        520
FT                   /note="S -> T (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        719
FT                   /note="A -> V (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        837
FT                   /note="G -> E (in Ref. 2; CAA34438)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        837
FT                   /note="G -> W (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        863
FT                   /note="G -> R (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        894
FT                   /note="R -> K (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        917..919
FT                   /note="SPS -> RPG (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        952
FT                   /note="G -> A (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        967..968
FT                   /note="QS -> HP (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        982
FT                   /note="P -> PL (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1022
FT                   /note="Missing (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1045
FT                   /note="R -> G (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1103
FT                   /note="T -> S (in Ref. 1; AAA51561)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:6AMV"
FT   STRAND          39..44
FT                   /evidence="ECO:0007829|PDB:6AMV"
FT   TURN            45..47
FT                   /evidence="ECO:0007829|PDB:6AMV"
FT   HELIX           49..53
FT                   /evidence="ECO:0007829|PDB:2FO0"
FT   HELIX           58..60
FT                   /evidence="ECO:0007829|PDB:2FO0"
FT   STRAND          65..70
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   STRAND          76..79
FT                   /evidence="ECO:0007829|PDB:3EG3"
FT   STRAND          87..93
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   STRAND          97..104
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   STRAND          107..112
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   HELIX           113..115
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:5OAZ"
FT   HELIX           122..124
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          128..131
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   HELIX           134..140
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   TURN            141..143
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          148..153
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          155..157
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          161..167
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          170..175
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          177..179
FT                   /evidence="ECO:0007829|PDB:4XEY"
FT   TURN            180..182
FT                   /evidence="ECO:0007829|PDB:4XEY"
FT   STRAND          184..187
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          190..194
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   HELIX           195..202
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:5DC4"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:5MO4"
FT   STRAND          229..231
FT                   /evidence="ECO:0007829|PDB:2GQG"
FT   TURN            233..235
FT                   /evidence="ECO:0007829|PDB:2G1T"
FT   HELIX           239..241
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          242..247
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           248..251
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          254..261
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           262..264
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          266..271
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   TURN            275..277
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           280..290
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          301..305
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          307..310
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          312..316
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          319..322
FT                   /evidence="ECO:0007829|PDB:2HZI"
FT   HELIX           323..329
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   TURN            332..334
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           337..356
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          359..361
FT                   /evidence="ECO:0007829|PDB:2G2H"
FT   HELIX           366..368
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           373..375
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          377..379
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           381..383
FT                   /evidence="ECO:0007829|PDB:2G2F"
FT   HELIX           384..387
FT                   /evidence="ECO:0007829|PDB:2G1T"
FT   HELIX           390..392
FT                   /evidence="ECO:0007829|PDB:2G1T"
FT   STRAND          393..396
FT                   /evidence="ECO:0007829|PDB:3QRJ"
FT   STRAND          399..401
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           403..405
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           408..413
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           418..433
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           445..447
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           448..453
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           466..475
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           480..482
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   HELIX           486..496
FT                   /evidence="ECO:0007829|PDB:5HU9"
FT   STRAND          498..500
FT                   /evidence="ECO:0007829|PDB:1OPL"
FT   HELIX           503..506
FT                   /evidence="ECO:0007829|PDB:2G1T"
FT   TURN            510..512
FT                   /evidence="ECO:0007829|PDB:2F4J"
FT   HELIX           1029..1045
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   TURN            1046..1048
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   HELIX           1053..1070
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   HELIX           1071..1073
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   HELIX           1080..1097
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   STRAND          1101..1104
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   STRAND          1106..1108
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   HELIX           1115..1128
FT                   /evidence="ECO:0007829|PDB:1ZZP"
FT   LIPID           P00519-2:2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1130 AA;  122873 MW;  85FE6C1C0E483EA2 CRC64;
     MLEICLKLVG CKSKKGLSSS SSCYLEEALQ RPVASDFEPQ GLSEAARWNS KENLLAGPSE
     NDPNLFVALY DFVASGDNTL SITKGEKLRV LGYNHNGEWC EAQTKNGQGW VPSNYITPVN
     SLEKHSWYHG PVSRNAAEYL LSSGINGSFL VRESESSPGQ RSISLRYEGR VYHYRINTAS
     DGKLYVSSES RFNTLAELVH HHSTVADGLI TTLHYPAPKR NKPTVYGVSP NYDKWEMERT
     DITMKHKLGG GQYGEVYEGV WKKYSLTVAV KTLKEDTMEV EEFLKEAAVM KEIKHPNLVQ
     LLGVCTREPP FYIITEFMTY GNLLDYLREC NRQEVNAVVL LYMATQISSA MEYLEKKNFI
     HRDLAARNCL VGENHLVKVA DFGLSRLMTG DTYTAHAGAK FPIKWTAPES LAYNKFSIKS
     DVWAFGVLLW EIATYGMSPY PGIDLSQVYE LLEKDYRMER PEGCPEKVYE LMRACWQWNP
     SDRPSFAEIH QAFETMFQES SISDEVEKEL GKQGVRGAVS TLLQAPELPT KTRTSRRAAE
     HRDTTDVPEM PHSKGQGESD PLDHEPAVSP LLPRKERGPP EGGLNEDERL LPKDKKTNLF
     SALIKKKKKT APTPPKRSSS FREMDGQPER RGAGEEEGRD ISNGALAFTP LDTADPAKSP
     KPSNGAGVPN GALRESGGSG FRSPHLWKKS STLTSSRLAT GEEEGGGSSS KRFLRSCSAS
     CVPHGAKDTE WRSVTLPRDL QSTGRQFDSS TFGGHKSEKP ALPRKRAGEN RSDQVTRGTV
     TPPPRLVKKN EEAADEVFKD IMESSPGSSP PNLTPKPLRR QVTVAPASGL PHKEEAGKGS
     ALGTPAAAEP VTPTSKAGSG APGGTSKGPA EESRVRRHKH SSESPGRDKG KLSRLKPAPP
     PPPAASAGKA GGKPSQSPSQ EAAGEAVLGA KTKATSLVDA VNSDAAKPSQ PGEGLKKPVL
     PATPKPQSAK PSGTPISPAP VPSTLPSASS ALAGDQPSST AFIPLISTRV SLRKTRQPPE
     RIASGAITKG VVLDSTEALC LAISRNSEQM ASHSAVLEAG KNLYTFCVSY VDSIQQMRNK
     FAFREAINKL ENNLRELQIC PATAGSGPAA TQDFSKLLSS VKEISDIVQR
//
